Nektar Therapeutics (NASDAQ: NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Doctors report a steady increase in eczema cases among infants across Indian cities. Experts warn that genetics and ...

Figure skater Michelle Hong used to hide her skin as much as possible due to her condition—but with effective treatment and ...

Welcome to DM a Derm, where GLAMOUR's resident dermatologists help solve your sk-inquiries. DM us at @glamouruk.

Nektar Therapeutics stock launched Tuesday after the biotech company hit every goal in a midstage study of its eczema ...

When somebody's coming in that has a known diagnosis of atopic dermatitis or eczema and things are really revved up still, if ...

Biologic medications have emerged as game-changers for moderate to severe eczema cases. Dupixent and Adbry target specific immune system components responsible for the inflammatory cascade that ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.